Skip to main content
Premium Trial:

Request an Annual Quote

Levin Out as CEO of Physiome; Company to Unveil New Business Plan in Two Weeks

NEW YORK, May 22 - Physiome Sciences CEO Jeremy Levin has left the company, which is in the midst of reorganizing itself, GenomeWeb has learned.


Levin left approximately one month ago, according to an insider. His name has been removed from the management portion of the company's web site, though he is still listed as a board member.


Nicholas Hayes, chief operating officer, has assumed the duties of Levin. Hayes joined Physiome in September 2002. Levin had been president and CEO since 1996.


Peter Brooks, vice president of business development and acting vice president for modeling and biological sciences, told GenomeWeb that Physiome will unveil a "new direction" in two weeks.


He would not comment when asked to clarify whether the new direction would entail lay offs. It was also unclear what will happen with the company's R&D collaborations, which include deals with 3rd Millennium and IBM.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.